AbbVie is seeking a new way to fight chronic lymphocytic leukemia by combining its oncology drug Venclexta with another ...

After a decade of development, a Kansas City-based pharmaceutical company is on the brink of submitting its ADHD medication ...

Johnson & Johnson (NYSE:JNJ) is one of the best trade‑war resistant stocks to buy now. On July 21, 2025, J&J submitted a New ...

Shares of Zymeworks were higher after the Food and Drug Administration cleared the company's investigational new drug application for its treatment for liver cancer. The stock rose 8.5%, to $14.46, in ...

AbbVie submitted a supplemental new drug application for Venclexta plus Calquence treatment in previously untreated chronic ...

Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...

AbbVie seeks FDA approval for a groundbreaking oral treatment combining venetoclax and acalabrutinib, promising a new era in ...

Submission of NDA for LNZ100 in China by CORXEL Pharmaceuticals results in achievement of first milestone due to LENZ under the Development and Commercialization Agreement ...

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a California-based company specializing in cortisol modulation through ...

LENZ Therapeutics previously licensed Greater China rights to CORXEL for the development and commercialization of LNZ100 in ...